BTIG Maintains Buy on Mereo BioPharma Group, Lowers Price Target to $1
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Julian Harrison maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers the price target from $6 to $1.
BTIG analyst Julian Harrison maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers the price target from $6 to $1.